John Franklin Fowler's Insider Trades & SAST Disclosures
John Franklin Fowler's most recent trade in Kezar Life Sciences Inc was a trade of 5,000 Stock Option (right to buy) done . Disclosure was reported to the exchange on Feb. 14, 2025.
Add Superstar Alert
Share
Note
This is a custom search result for pattern John Franklin Fowler.To see full superstar portfolios of large investors like Warren Buffet, Elon Musk and others, click here.
Advanced/Help
"Balanced Fund": Use this format with quotation marks to find the exact phrase. The output matches
"Balanced Fund"
but not "Balanced Growth Fund"
Balanced Fund: Use this format without quotation marks to search for all funds related to the term
"Balanced Fund" The results may include
"Balanced Income Fund", "Balanced Growth Fund" and any fund name containing "Balanced Fund".
| Stock | Client Name | Client Category | Action | Reported to Exchange | Quantity | Post Transaction Holding | Traded % | Avg. Price | Value | Security Type |
|---|---|---|---|---|---|---|---|---|---|---|
| Kezar Life Sciences Inc | John Franklin Fowler | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 14 Feb 2025 | 5,000 | 5,000 | - | - | Stock Option (right to buy) | |
| Kezar Life Sciences Inc | John Franklin Fowler | Director, CEO | Sale or transfer of securities back to the company at price $ 0.00 per share. | 24 Jul 2023 | 1,200,000 | 0 | - | - | Employee Stock Option (right to buy) | |
| Kezar Life Sciences Inc | John Franklin Fowler | Director, CEO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 24 Jul 2023 | 1,200,000 | 1,200,000 | - | - | Employee Stock Option (right to buy) | |
| Kezar Life Sciences Inc | John Franklin Fowler | Director, CEO | Sale or transfer of securities back to the company at price $ 0.00 per share. | 24 Jul 2023 | 580,000 | 0 | - | - | Employee Stock Option (right to buy) | |
| Kezar Life Sciences Inc | John Franklin Fowler | Director, CEO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 24 Jul 2023 | 580,000 | 580,000 | - | - | Employee Stock Option (right to buy) | |
| Kezar Life Sciences Inc | John Franklin Fowler | Director, CEO | Sale or transfer of securities back to the company at price $ 0.00 per share. | 24 Jul 2023 | 500,000 | 0 | - | - | Employee Stock Option (right to buy) | |
| Kezar Life Sciences Inc | John Franklin Fowler | Director, CEO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 24 Jul 2023 | 500,000 | 500,000 | - | - | Employee Stock Option (right to buy) | |
| Kezar Life Sciences Inc | John Franklin Fowler | Director, CEO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 24 Jul 2023 | 200,000 | 200,000 | - | - | Employee Stock Option (right to buy) | |
| Kezar Life Sciences Inc | John Franklin Fowler | Director, CEO | Sale or transfer of securities back to the company at price $ 0.00 per share. | 24 Jul 2023 | 200,000 | 0 | - | - | Employee Stock Option (right to buy) | |
| Kezar Life Sciences Inc | John Franklin Fowler | Director, CEO | Sale or transfer of securities back to the company at price $ 0.00 per share. | 24 Jul 2023 | 175,000 | 0 | - | - | Employee Stock Option (right to buy) | |
| Kezar Life Sciences Inc | John Franklin Fowler | Director, CEO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 24 Jul 2023 | 175,000 | 175,000 | - | - | Employee Stock Option (right to buy) | |
| Kezar Life Sciences Inc | John Franklin Fowler | Director, CEO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 08 Jan 2023 | 580,000 | 580,000 | - | - | Employee Stock Option (right to buy) | |
| Kezar Life Sciences Inc | John Franklin Fowler | Director, CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 10 Nov 2022 | 27,000 | 55,721 | - | - | Employee Stock Option (Right to Buy) | |
| Kezar Life Sciences Inc | John Franklin Fowler | Director, CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.90 per share. | 10 Nov 2022 | 27,000 | 393,904 (1%) | 0% | 0.9 | 24,300 | Common Stock |
| Kezar Life Sciences Inc | John Franklin Fowler | Director, CEO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 05 Jan 2022 | 500,000 | 500,000 | - | - | Employee Stock Option (right to buy) | |
| Kezar Life Sciences Inc | John Franklin Fowler | Director, CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 14 Dec 2021 | 7,700 | 82,721 | - | - | Employee Stock Option (Right to Buy) | |
| Kezar Life Sciences Inc | John Franklin Fowler | Director, CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.90 per share. | 14 Dec 2021 | 7,700 | 366,904 (0%) | 0% | 0.9 | 6,930 | Common Stock |
| Kezar Life Sciences Inc | John Franklin Fowler | Director, CEO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 08 Jan 2021 | 1,200,000 | 1,200,000 | - | - | Employee Stock Option (right to buy) |
*All Values are in $ Million
Client Category: Promoter/ KMP/ Director / Immediate Relatives / Employee / etc
Security Type: Share/ Warrants / Convertible Debentures
Security Type: Share/ Warrants / Convertible Debentures
Data as reported to USA Exchanges